86 related articles for article (PubMed ID: 3456073)
21. Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia.
Schwartz RS; Mackintosh FR; Halpern J; Schrier SL; Greenberg PL
Cancer; 1984 Oct; 54(8):1672-81. PubMed ID: 6592033
[TBL] [Abstract][Full Text] [Related]
22. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
Niederwieser C; Nicolet D; Carroll AJ; Kolitz JE; Powell BL; Kohlschmidt J; Stone RM; Byrd JC; Mrózek K; Bloomfield CD
Haematologica; 2016 Dec; 101(12):1516-1523. PubMed ID: 27470602
[TBL] [Abstract][Full Text] [Related]
23. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M;
Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.
Ismail MM; Abdulateef NAB
Int J Hematol; 2017 Apr; 105(4):453-464. PubMed ID: 27910003
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL)].
Yang H; Niu JH; Zhu CY; Zhang Q; Zhu HY; Yao ZL; Zhou MH; Wang QS; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):957-64. PubMed ID: 25130810
[TBL] [Abstract][Full Text] [Related]
26. [Various aspects of bone marrow cell proliferation in acute leukemia].
Shmarov DA; Kuchma IuM; Kozinets GI
Ter Arkh; 2001; 73(12):73-7. PubMed ID: 11858117
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy.
Wu S; Yang S; Zhu L; Wang Y; Zhang Y; Zhou J; Li D
Am J Med Sci; 2016 May; 351(5):473-9. PubMed ID: 27140705
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
[TBL] [Abstract][Full Text] [Related]
29. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
[TBL] [Abstract][Full Text] [Related]
30. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.
Kantarjian HM; Barlogie B; Keating MJ; Hall RR; Smith TL; McCredie KB; Freireich EJ
J Clin Invest; 1985 Jul; 76(1):319-24. PubMed ID: 3860508
[TBL] [Abstract][Full Text] [Related]
32. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
33. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
[TBL] [Abstract][Full Text] [Related]
35. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
37. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
38. [Studies on cell kinetics in leukemia using flow cytometry].
Yoshida K
Hokkaido Igaku Zasshi; 1982 Sep; 57(5):557-71. PubMed ID: 7152463
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of hematogones in patients with acute myeloid leukemia.
Chantepie SP; Parienti JJ; Salaun V; Benabed K; Cheze S; Gac AC; Johnson-Ansah H; Macro M; Damaj G; Vilque JP; Reman O
Am J Hematol; 2016 Jun; 91(6):566-70. PubMed ID: 26934680
[TBL] [Abstract][Full Text] [Related]
40. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
